Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of Response to Preoperative Chemotherapy Versus Surgery Alone in Gastroesophageal Cancer: Tumor Resectability, Pathologic Results and Post-Operative Complications

  • Marandi, Aref Kashefi (Department of Surgery, Shariati Hospital, Tehran University of Medical Sciences) ;
  • Shojaiefard, Abolfazl (Department of Surgery, Shariati Hospital, Tehran University of Medical Sciences) ;
  • Soroush, Ahmadreza (Department of Surgery, Shariati Hospital, Tehran University of Medical Sciences) ;
  • Abdegah, Ali Ghorbani (Department of Surgery, Shariati Hospital, Tehran University of Medical Sciences) ;
  • Jafari, Mehdi (Department of Surgery, Shariati Hospital, Tehran University of Medical Sciences) ;
  • Khodadost, Mahmoud (Gastroenterology and Liver Research Center, Baqiyatallah University of Medical Sciences) ;
  • Mahmoudzade, Hossein (Department of Surgery, Shariati Hospital, Tehran University of Medical Sciences)
  • Published : 2016.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Gastroesophageal cancer is one of the most common types of cancer worldwide. Despite significant developments in management, 5-year survival in the developing world is less than 20 percent. Due to restricted research about the impact of preoperative chemotherapy (POC) on tumor resection, pathological response and postoperative complications in Iran, we designed and implemented the present retrospective cross- sectional study on 156 patients with gastroesophageal cancer (GEc) between 2013 and 2015 at Shariati Hospital of Tehran. Two groups were included, the first group had previously received preoperative chemotherapy and the second group had only undergone surgery. All patients were followed for at least one year after the operation in terms of tumor recurrence, relapse free survival and one-year survival. The two groups were eventually compared regarding tumor resection, pathological response, postoperative complications, recurrence rate and survival. The mean age was $66.5{\pm}7.3years$ and 78 percent were male. The tumor resectability, pathological response and postoperative complications in the group which received POC were 93.5%, 21.8% and 12.8%, respectively, and in the surgery alone group figures for tumor resection and postoperative complications were 76% and 29.5%, respectively. Also based on our study the 5-year survival in the POC group was better (79.5% vs. 66.5%). Using standard neoadjuvant regimens (preoperative chemotherapy/chemoradiotherapy) beforesurgery could increase tumor resectability, pathological response, and improve the general status of the patients. Therefore using POC may be recommended over surgery alone.

Keywords

References

  1. Ajani JA, Mansfield PF, Crane CH, et al (2005). Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol, 23, 1237-44. https://doi.org/10.1200/JCO.2005.01.305
  2. Allum WH, Stenning SP, Bancewicz J, et al (2009). Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol, 27, 5062-67. https://doi.org/10.1200/JCO.2009.22.2083
  3. Ando N, Iizuka T, Ide H, et al (2003). Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol, 21, 4592-96. https://doi.org/10.1200/JCO.2003.12.095
  4. Archie V, Kauh J, Jones DV, et al (2006). Gastric cancer: standards for the 21st century. Crit Rev Oncol Hematol, 57, 123-31. https://doi.org/10.1016/j.critrevonc.2005.09.004
  5. Berger AC, Farma J, Scott WJ, et al (2005). Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol, 23, 4330-37. https://doi.org/10.1200/JCO.2005.05.017
  6. Cunningham D, Allum WH, Stenning SP, et al (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 355, 11-20. https://doi.org/10.1056/NEJMoa055531
  7. Dikken JL, van de Velde CJ, Coit DG, et al (2012). Treatment of resectable gastric cancer. Therap Adv Gastroenterol, 5, 49-69. https://doi.org/10.1177/1756283X11410771
  8. Flamant Y CJ, Huguier M, Quandalle P, et al (1999). Chimiotherapie adjuvante apres resection des adenocarcinomes gastriques: etude prospective controlee de l'effet de l'association 5FU, acide folinique et cisplatine. Gastroenterol Clin Biol, 21, 16.
  9. Gebski V, Burmeister B, Smithers BM, et al (2007). Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol, 8, 226-34. https://doi.org/10.1016/S1470-2045(07)70039-6
  10. Information on the Dutch CRITICS trial [Online]. Available: http://clinicaltrials.gov/ct2/show/NCT00407186 [Accessed 14 December 2010].
  11. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  12. Kelsen DP, Ginsberg R, Pajak TF, et al (1998). Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med, 339, 1979-84. https://doi.org/10.1056/NEJM199812313392704
  13. Law S, Fok M, Chow S, et al (1997). Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg, 114, 210-7. https://doi.org/10.1016/S0022-5223(97)70147-8
  14. Lee DJ, Sohn TS, Lim DH, et al (2012). Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer. Cancer Chemother Pharmacol, 69, 1333-38. https://doi.org/10.1007/s00280-012-1836-8
  15. Ott K, Lordick F, Blank S, et al (2011). Gastric cancer: surgery in 2011. Langenbecks Arch Surg, 396, 743-58. https://doi.org/10.1007/s00423-010-0738-7
  16. Pera M, Gallego R, Montagut C, et al (2012). Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol, 23, 664-70. https://doi.org/10.1093/annonc/mdr291
  17. Sadighi S, Raafat J, Mohagheghi M, et al (2005). Gastric carcinoma: 5 year experience of a single institute. Asian Pac J Cancer Prev, 6, 195-6.
  18. Shigeoka H, Imamoto H, Nishimura Y, et al (2010). Complete response to preoperative chemoradiotherapy in highly advanced gastric adenocarcinoma. World J Gastrointest Oncol, 2, 282-6. https://doi.org/10.4251/wjgo.v2.i6.282
  19. Urba SG, Orringer MB, Turrisi A, et al (2001). Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol, 19, 305-13. https://doi.org/10.1200/JCO.2001.19.2.305
  20. Urschel JD, Vasan H (2003). A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg, 185, 538-43. https://doi.org/10.1016/S0002-9610(03)00066-7
  21. Valenti V, Hernandez-Lizoain JL, Beorlegui MC, et al (2011). Morbidity, mortality, and pathological response in patients with gastric cancer preoperatively treated with chemotherapy or chemoradiotherapy. J Surg Oncol, 104, 124-9. https://doi.org/10.1002/jso.21947
  22. Weber WA, Ott K, Becker K, et al (2001). Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol, 19, 3058-65. https://doi.org/10.1200/JCO.2001.19.12.3058
  23. Working MRCOC (2002). Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet, 359, 1727-33. https://doi.org/10.1016/S0140-6736(02)08651-8
  24. Ychou M, Boige V, Pignon J-P, et al (2011). Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol, 29, 1715-21. https://doi.org/10.1200/JCO.2010.33.0597